JP2007509607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509607A5 JP2007509607A5 JP2006530599A JP2006530599A JP2007509607A5 JP 2007509607 A5 JP2007509607 A5 JP 2007509607A5 JP 2006530599 A JP2006530599 A JP 2006530599A JP 2006530599 A JP2006530599 A JP 2006530599A JP 2007509607 A5 JP2007509607 A5 JP 2007509607A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleic acid
- acid construct
- antigen
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50993603P | 2003-10-10 | 2003-10-10 | |
| US60/509,936 | 2003-10-10 | ||
| PCT/GB2004/004279 WO2005035771A2 (en) | 2003-10-10 | 2004-10-11 | Nucleic acid constructs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509607A JP2007509607A (ja) | 2007-04-19 |
| JP2007509607A5 true JP2007509607A5 (enExample) | 2007-12-06 |
| JP4814099B2 JP4814099B2 (ja) | 2011-11-09 |
Family
ID=34435038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006530599A Expired - Fee Related JP4814099B2 (ja) | 2003-10-10 | 2004-10-11 | 核酸構築物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8663657B2 (enExample) |
| EP (1) | EP1685251B1 (enExample) |
| JP (1) | JP4814099B2 (enExample) |
| KR (2) | KR101225395B1 (enExample) |
| CN (1) | CN1890375B (enExample) |
| AU (1) | AU2004279991B2 (enExample) |
| BR (1) | BRPI0415204A (enExample) |
| CA (1) | CA2542288A1 (enExample) |
| DK (1) | DK1685251T3 (enExample) |
| EA (1) | EA010056B1 (enExample) |
| ES (1) | ES2457022T3 (enExample) |
| IL (1) | IL174848A (enExample) |
| MX (1) | MXPA06003978A (enExample) |
| NO (1) | NO20062080L (enExample) |
| NZ (1) | NZ546554A (enExample) |
| PL (1) | PL1685251T3 (enExample) |
| PT (1) | PT1685251E (enExample) |
| SG (1) | SG147430A1 (enExample) |
| SI (1) | SI1685251T1 (enExample) |
| WO (1) | WO2005035771A2 (enExample) |
| ZA (1) | ZA200603685B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
| CA2624615A1 (en) * | 2005-10-05 | 2007-04-19 | Bayhill Therapeutics, Inc. | Compositions and methods for treatment of autoimmune disease |
| EA201100225A1 (ru) | 2008-07-23 | 2011-08-30 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Новые регуляторные элементы |
| EP3318248B1 (en) * | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| CN101993878B (zh) * | 2010-10-14 | 2012-04-18 | 南京农业大学 | 一种rRNA嵌合启动子及含有该嵌合启动子的表达载体 |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| MX362981B (es) * | 2012-03-27 | 2019-02-28 | Curevac Ag | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. |
| WO2013143700A2 (en) * | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| SG11201405542UA (en) * | 2012-03-27 | 2014-10-30 | Curevac Gmbh | Artificial nucleic acid molecules |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| DK2711426T3 (en) * | 2012-09-24 | 2015-07-13 | Lonza Biologics Plc | Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences |
| EP2938726B1 (en) | 2012-12-31 | 2017-09-27 | Boehringer Ingelheim International GmbH | Heterologous intron within a signal peptide |
| WO2014102104A1 (en) * | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Artificial introns |
| WO2014102100A1 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Heterologous intron within an immunoglobulin domain |
| WO2014102101A1 (en) * | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Novel intron sequences |
| RS57739B1 (sr) | 2013-03-14 | 2018-12-31 | Translate Bio Inc | Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima |
| JP6586075B2 (ja) | 2013-03-14 | 2019-10-02 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| CN106413811A (zh) | 2013-10-22 | 2017-02-15 | 夏尔人类遗传性治疗公司 | 精氨基琥珀酸合成酶缺乏症的mrna疗法 |
| JP6506749B2 (ja) | 2013-10-22 | 2019-04-24 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
| CN111304231A (zh) * | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CN103901209B (zh) * | 2014-02-18 | 2016-05-25 | 王明丽 | 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒 |
| US9850269B2 (en) | 2014-04-25 | 2017-12-26 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| US10563222B2 (en) * | 2014-06-18 | 2020-02-18 | Agency For Science, Technology And Research | Promoters for high level expression |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| US20200377887A1 (en) * | 2017-09-22 | 2020-12-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| KR102950141B1 (ko) | 2018-08-24 | 2026-04-07 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 정제 방법 |
| WO2020106946A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP4031662A1 (en) | 2019-09-20 | 2022-07-27 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3431140A1 (de) | 1984-08-24 | 1986-03-06 | Behringwerke Ag, 3550 Marburg | Enhancer fuer eukaryotische expressionssysteme |
| US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| TW360548B (en) | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
| DK0690732T3 (da) | 1994-01-21 | 2003-05-19 | Powderject Vaccines Inc | Gasdrevet genindførselsinstrument |
| ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| DE69624815T2 (de) * | 1995-05-24 | 2003-07-10 | Hawaii Biotech Group | Untereinheitsimpfstoff gegen flavivirus infektion |
| US6110707A (en) * | 1996-01-19 | 2000-08-29 | Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
| GB9715064D0 (en) * | 1997-07-17 | 1997-09-24 | Ppl Therapeutics Scotland Ltd | Protein expression |
| US20020106635A1 (en) | 1998-05-27 | 2002-08-08 | Bruce Freimark | Cytokine resistant cytomegalovirus promoter mutants and related products and methods |
| NZ511798A (en) * | 1998-10-19 | 2004-01-30 | Powderject Vaccines Inc | Minimal promoters comprising a promoter not linked to its native enhancer and such minimal promoters linked to an antigen |
| CA2400488A1 (en) | 2000-02-08 | 2001-08-16 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of infections using anti-c3b(i) antibodies |
| GB0027088D0 (en) * | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
| US20030124523A1 (en) * | 2000-06-22 | 2003-07-03 | Asselbergs Fredericus Alphonsus Maria | Organic compounds |
| ES2261489T3 (es) | 2000-10-13 | 2006-11-16 | Chiron Corporation | Fragmentos de intron a de citomegalovirus. |
| DK1379273T3 (da) | 2000-11-27 | 2009-11-09 | Powderject Vaccines Inc | Nukleinsyreadjuvanser |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| JP2004535799A (ja) * | 2001-05-18 | 2004-12-02 | パウダージェクト ワクチンズ，インコーポレーテッド | ワクチン組成物 |
| GB0118367D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
| EA012066B1 (ru) | 2003-10-10 | 2009-08-28 | Паудерджект Вэксинс, Инк. | Способ, вызывающий т-клеточный ответ |
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
-
2004
- 2004-10-11 PT PT47688114T patent/PT1685251E/pt unknown
- 2004-10-11 MX MXPA06003978A patent/MXPA06003978A/es active IP Right Grant
- 2004-10-11 SI SI200432144T patent/SI1685251T1/sl unknown
- 2004-10-11 CN CN2004800367871A patent/CN1890375B/zh not_active Expired - Fee Related
- 2004-10-11 DK DK04768811.4T patent/DK1685251T3/en active
- 2004-10-11 JP JP2006530599A patent/JP4814099B2/ja not_active Expired - Fee Related
- 2004-10-11 ES ES04768811.4T patent/ES2457022T3/es not_active Expired - Lifetime
- 2004-10-11 KR KR1020067009012A patent/KR101225395B1/ko not_active Expired - Fee Related
- 2004-10-11 SG SG200807573-1A patent/SG147430A1/en unknown
- 2004-10-11 EP EP04768811.4A patent/EP1685251B1/en not_active Expired - Lifetime
- 2004-10-11 AU AU2004279991A patent/AU2004279991B2/en not_active Ceased
- 2004-10-11 NZ NZ546554A patent/NZ546554A/en not_active IP Right Cessation
- 2004-10-11 CA CA002542288A patent/CA2542288A1/en not_active Abandoned
- 2004-10-11 KR KR1020117024399A patent/KR101234981B1/ko not_active Expired - Fee Related
- 2004-10-11 BR BRPI0415204-2A patent/BRPI0415204A/pt active Search and Examination
- 2004-10-11 WO PCT/GB2004/004279 patent/WO2005035771A2/en not_active Ceased
- 2004-10-11 PL PL04768811T patent/PL1685251T3/pl unknown
- 2004-10-11 EA EA200600746A patent/EA010056B1/ru not_active IP Right Cessation
- 2004-10-11 US US10/575,087 patent/US8663657B2/en not_active Expired - Fee Related
-
2006
- 2006-04-06 IL IL174848A patent/IL174848A/en active IP Right Review Request
- 2006-05-09 ZA ZA200603685A patent/ZA200603685B/en unknown
- 2006-05-09 NO NO20062080A patent/NO20062080L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509607A5 (enExample) | ||
| JP6903120B2 (ja) | アルファウイルスワクチン接種のための組成物及び方法 | |
| JP2025084808A (ja) | エプスタイン－バーウイルスワクチン | |
| CN104884082B (zh) | 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 | |
| CN116390752A (zh) | 自扩增性sars-cov-2rna疫苗 | |
| Qi et al. | Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection | |
| US6831169B2 (en) | Hepatitis C virus vaccine | |
| WO2020063370A2 (zh) | 免疫组合物及其制备方法与应用 | |
| WO2000011140A1 (en) | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting | |
| CN101573449B (zh) | 用于治疗慢性乙型肝炎的dna疫苗及其制备方法 | |
| CA2447450A1 (en) | Corona-virus-like particles comprising functionally deleted genomes | |
| JP2021509107A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよびその使用 | |
| JP2008528020A (ja) | 核酸構築物 | |
| US20240335531A1 (en) | Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection | |
| CN114729010B (zh) | 乙型肝炎病毒疫苗 | |
| JP2023546603A (ja) | 外来抗原をコードする遺伝物質を含む、ターゲット組織の大きさまたは体積の縮小用のワクチン組成物またはキット | |
| WO2022077591A1 (zh) | 一种重组腺病毒在制备预防病毒的药物中的用途 | |
| WO2020254876A1 (en) | Virus-like particle delivery of hepatitis b virus (hbv) vaccines | |
| WO2020255015A1 (en) | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators | |
| Zhou et al. | Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine | |
| CN117018175A (zh) | 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用 | |
| CN103239717B (zh) | 治疗慢性乙型肝炎的复制子dna疫苗 | |
| KR102766523B1 (ko) | 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트 | |
| EP4574168A1 (en) | Prime-boost immunization against influenza | |
| Shiau et al. | Analysis of Humoral Immunity of Hepatitis D Virus DNA Vaccine Generated in Mice by Using Different Dosage, Gene Gun Immunization, andIn VivoElectroporation |